XBiotech Inc. (NASDAQ:XBIT) traded down 7% on Wednesday . The company traded as low as $14.51 and last traded at $14.51, with a volume of 68,670 shares changing hands. The stock had previously closed at $15.60.

A number of equities research analysts have recently weighed in on the company. Noble Financial reiterated a “buy” rating and issued a $30.00 price target (up from $24.00) on shares of XBiotech in a report on Tuesday, June 28th. Zacks Investment Research upgraded XBiotech from a “hold” rating to a “buy” rating and set a $15.00 price target for the company in a report on Tuesday, May 24th.

The stock’s 50-day moving average price is $15.20 and its 200-day moving average price is $13.11. The company’s market capitalization is $458.73 million.

In related news, Director W Thorpe Mckenzie purchased 20,000 shares of the firm’s stock in a transaction dated Thursday, May 26th. The stock was bought at an average price of $13.96 per share, for a total transaction of $279,200.00. Following the purchase, the director now owns 3,898,600 shares in the company, valued at approximately $54,424,456. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

XBiotech Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of diseases. The Company focuses on bringing its lead product candidate, Xilonix (MABp1), to market. The Company has also developed a True Human monoclonal antibody discovery platform and manufacturing system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.